Neurological Disorders clinical trials

Explore recruiting neurological disorders clinical trials.

Recruiting neurological disorders studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Neurological Disorders trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Impact of CHOlinergic Stimulation on COgnitive and MOtor Functions and Brain Activity in Elderly Volunteers (CHOCOMO) - a randomised, placebo-controlled trial

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

Migraine and High Flow Oxygenotherapy at the Emergency Department (MiOx)

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3 Global, Randomized, Double-Blind, Placebo-Controlled, 48-Week, Parallel-Group Study of the Efficacy and Safety of Losmapimod in Treating Patients With Facioscapulohumeral Muscular Dystrophy (FSHD) (REACH)

Italy, Spain, France, Germany, Netherlands, Denmark

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous AOC 1020 for the Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD)

Italy, France, Germany, Spain, Denmark, Netherlands

Therapeutic confirmatory (Phase III) EU CTIS Study details

An Open-Label, Multicenter Extension Study Evaluating the Patient Perspective of the Physical Impact of Multiple Sclerosis and Providing Continued Access to Ocrelizumab in Patients with Multiple Sclerosis Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Study and without Access to A Post Trial Access Program

France, Germany, Bulgaria

Therapeutic confirmatory (Phase III) EU CTIS Study details

Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells

Spain, Netherlands, France, Germany, Austria, Belgium +1 more

Therapeutic exploratory (Phase II) EU CTIS Study details

Neurological Disorders trials by city

Neurological Disorders in Toronto Neurological Disorders in Vancouver Neurological Disorders in Montreal Neurological Disorders in Calgary Neurological Disorders in Edmonton Neurological Disorders in Ottawa Neurological Disorders in Winnipeg Neurological Disorders in Quebec City Neurological Disorders in Hamilton Neurological Disorders in Kitchener Neurological Disorders in London Neurological Disorders in Halifax Neurological Disorders in New York Neurological Disorders in Los Angeles Neurological Disorders in Chicago Neurological Disorders in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease